NCT04425434 Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
| NCT ID | NCT04425434 |
| Status | Recruiting |
| Phase | — |
| Sponsor | French Africa Pediatric Oncology Group |
| Condition | Retinoblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2020-11-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2020-11-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.
Eligibility Criteria
Inclusion Criteria: * Unilateral intraocular Retinoblastoma (RB) * Unilateral extraocular intraorbital (RB) * Bilateral intraocular (RB) * bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side. Exclusion Criteria: * Externalized tumor mass * massive extension to optic nerve up to optical channeltumor * intracranial extension leptomeninges * cerebral parenchyma * extension to regional lymph nodes and/or remote metastases. * cerebrospinal fluid involvement. * Trilateral RB * Incapacity to followed the whole treatement.
Contact & Investigator
FOUSSEYNI Mr TRAORE, Dr;
PRINCIPAL INVESTIGATOR
AMCC AND GFAOP
Frequently Asked Questions
Who can join the NCT04425434 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Retinoblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04425434 currently recruiting?
Yes, NCT04425434 is actively recruiting participants. Contact the research team at drassanik@gmail.com for enrollment information.
Where is the NCT04425434 trial being conducted?
This trial is being conducted at Ouagadougou, Burkina Faso, Abidjan, Côte d’Ivoire, Kinshasa, Democratic Republic of the Congo, Lubumbashi, Democratic Republic of the Congo and 3 additional locations.
Who is sponsoring the NCT04425434 clinical trial?
NCT04425434 is sponsored by French Africa Pediatric Oncology Group. The principal investigator is FOUSSEYNI Mr TRAORE, Dr; at AMCC AND GFAOP. The trial plans to enroll 3,000 participants.